Research programme: hepatitis C virus non-structural protein modulators - Valneva

Drug Profile

Research programme: hepatitis C virus non-structural protein modulators - Valneva

Alternative Names: CVVS 732; CVVS-59911; VLS 732; VLS-702; VLS-801

Latest Information Update: 12 Jul 2013

Price : $50

At a glance

  • Originator Vivalis
  • Developer Valneva
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein modulators; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 19 May 2012 Adverse events and pharmacokinetics data from a preclinical study in Hepatitis C released by Vivalis
  • 18 Apr 2012 Pharmacodynamics data from a preclinical studies in Hepatitis C released by Vivalis ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top